Yumeng Zhang, MD
![Yumeng Zhang](/globalassets/images/providers_bio/ZhangYumeng_25093.jpg)
Yumeng Zhang, MD
Specialty: Hematology/Oncology
Program: Malignant Hematology
Language(s): English, Mandarin Chinese
-
Overview
Cancer Focus:
Cutaneous Lymphoma (CTCL), Hodgkin Lymphoma, Non-Hodgkin LymphomaDr. Zhang received her MD degree from the University of South Florida, Morsani College of Medicine. She completed an Internal Medicine Residency at the University of South Florida, followed by a Hematology and Medical Oncology Fellowship at Moffitt Cancer Center and the University of South Florida, where she also served as Chief Fellow. Dr. Zhang is a recent recipient of the ASCO Robert A. Winn Diversity in Clinical Trials Award. Dr. Zhang’s clinical interests focus on improving patient outcomes in non-Hodgkin lymphoma through the application of personalized cancer treatment strategies. Her research interests are centered around T-cell malignancies, particularly cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma and B-cell lymphoma. She is focused on investigating the underlying molecular and immunological mechanisms of these malignancies, with the goal of developing innovative therapeutic approaches that can lead to improved outcomes and personalized care.
-
Publications
- Rutenberg D, Zhang Y, Montoya JG, Sinnott J, Contopoulos-Ioannidis DG. The Meat of the Matter. N Engl J Med. 2024 May.390(17):1612-1618. Pubmedid: 38692295.
- Zhang Y, Rose A, Khadka S, Cao B, Eatrides J, Saeed H, Shah BD, Chavez J, Bello C, Lazaryan A, Khimani F, Ibarz JP, Liu HD, Locke FL, Jain MD, Zhang L, Kharfan-Dabaja MA, Kim J, Ayala E, Nishihori T, Sokol L. Autologous Hematopoietic Cell Transplantation Consolidation for First Response is Associated With Longer Survival Among Patients With Nodal Peripheral T Cell Lymphoma. Transplant Cell Ther. 2024 May. Pubmedid: 38740140.
- Zhang Y, Darville L, Hogue S, Hallanger Johnson JE, Rose T, Kim Y, Bailey A, Gray JE, Robinson LA. High Pretreatment DHEA Is Associated with Inferior Immunotherapy Response in Metastatic Non-Small Cell Lung Cancer. Cancers (Basel). 2024 Mar.16(6). Pubmedid: 38539486. Pmcid: PMC10968948.
- Harro CM, Sprenger KB, Chaurio RA, Powers JJ, Innamarato P, Anadon CM, Zhang Y, Biswas S, Mandal G, Mine JA, Cortina C, Nagy MZ, Martin AL, Handley KF, Borjas GJ, Chen PL, Pinilla-Ibarz J, Sokol L, Yu X, Conejo-Garcia JR. Sézary syndrome originates from heavily mutated hematopoietic progenitors. Blood Adv. 2023 Sep.7(18):5586-5602. Pubmedid: 37531660. Pmcid: PMC10514084.
- Zhang Y, Nguyen L, Lu CM, Wang E, Lauw MIS, Ball S, Dong N, Moscinski L, Chan O, Yun S, Sallman D, Sokol L, Shah B, Knepper T, Lancet J, Komrokji R, Padron E, Kuykendall A, Zhang L. Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion. Clin Lymphoma Myeloma Leuk. 2023 Mar.23(3):e150-e163. Pubmedid: 36624015.
- Zhang L, Shah B, Zhang Y, Tashkandi H, Xiao W, Fernandez-Pol S, Vergara-Lluri M, Hussaini M, Song J, Lancet J, Moscinski L, Yun S, Lu CM, Medeiros LJ, Tang G. Clinicopathologic characteristics, genetic features, and treatment options for acute lymphoblastic leukemia with JAK2 rearrangement-A 10-case study and literature review. Hum Pathol. 2023 Jun.136:1-15. Pubmedid: 36958463.
- Ball S, Jain AG, Aguirre LE, Al Ali N, Zhang Y, Chan O, Kuykendall AT, Sweet KL, Lancet JE, Swoboda DM, Padron E, Komrokji RS, Sallman DA. Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: Is the combination indeed better?. Am J Hematol. 2022 May.97(5):E185-E188. Pubmedid: 35179241.
- Zhang Y, Seminario-Vidal L, Cohen L, Hussaini M, Yao J, Rutenberg D, Kim Y, Giuliano A, Robinson LA, Sokol L. "Alterations in the Skin Microbiota Are Associated With Symptom Severity in Mycosis Fungoides". Front Cell Infect Microbiol. 2022 May.12:850509. Pubmedid: 35656034. Pmcid: PMC9152451.
- Zhang Y, Sokol L. Clinical Insights into the Management of Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancer Manag Res. 2022 Jun.14:2107-2117. Pubmedid: 35789956. Pmcid: PMC9250318.
- Zhang Y, Seminario-Vidal L, Varnadoe C, Lu Y, Dong N, Salamanca C, Whiddon S, Bennett J, Hargis R, Liu H, Montejo M, Hussaini M, Harro C, Messina J, Benson K, Pinilla-Ibarz J, Conejo-Garcia J, Sokol L. Clinical characteristics and prognostic factors of 70 patients with Sézary syndrome: a single-institutional experience at Moffitt cancer center. Leuk Lymphoma. 2022 Jan.63(1):109-116. Pubmedid: 34467825. Pmcid: PMC9167451.
- Zhang Y, Duncanson L, Brayer J, Reu F, Hansen D, Alsina M, Nishihori T, Ochoa-Bayona J, Liu H, Shain K, Thompson Z, Baz R, Blue B. Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective Study. Clin Lymphoma Myeloma Leuk. 2022 Aug.22(8):e770-e776. Pubmedid: 35504808.
- Zhang Y, Kumar P, Adashek JJ, Skelton WP, Li J, Vosoughi A, Chahoud J, Manley BJ, Spiess PE. Adding Cyclooxygenase Inhibitors to Immune Checkpoint Inhibitors Did Not Improve Outcomes in Metastatic Renal Cell Carcinoma. Cells. 2022 Aug.11(16). Pubmedid: 36010582. Pmcid: PMC9406439.
- Gesiotto Q, Zhang Y, Malik A, Seminario-Vidal L, Ayala E, Zhang L, Sokol L. Long-Term Remission After Matched Sibling Donor Hematopoietic Cell Transplantation in a Patient With Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma. Cureus. 2021 May.13(5):e15132. Pubmedid: 34159034. Pmcid: PMC8214246.
- Dong N, Castillo Tokumori F, Isenalumhe L, Zhang Y, Tandon A, Knepper TC, Mo Q, Shao H, Zhang L, Sokol L. Large granular lymphocytic leukemia - A retrospective study of 319 cases. Am J Hematol. 2021 Jul.96(7):772-780. Pubmedid: 33819354.
- Adashek JJ, Zhang Y, Skelton WP, Bilotta A, Chahoud J, Zemp L, Li J, Dhillon J, Manley B, Spiess PE. Dissecting Outcomes: Should Cytoreductive Nephrectomy Be Performed for Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation?. Front Oncol. 2021 Feb.10:627025. Pubmedid: 33643921. Pmcid: PMC7902859.
- Zhang Y, Lee D, Gesiotto Q, Sokol L. Aggressive natural killer cell leukemia: diagnosis, treatment recommendations, and emerging therapies. Expert Rev Hematol. 2021 Aug.14(8):731-740. Pubmedid: 34263714.
- Visweshwar N, Zhang Y, Joseph H, Jaglal M, Ayala I. Chronic pain in patients with hemophilia: is it preventable?. Blood Coagul Fibrinolysis. 2020 Sep.31(6):346-352. Pubmedid: 32815911.
- Zhang Y, Varnadoe C, Tandon A, Forsyth P, Komrokji R, Sokol L. Myasthenia Gravis and Large Granular Lymphocytic Leukemia: a rare association. Leuk Res Rep. 2020 Oct.14:100226. Pubmedid: 33094093. Pmcid: PMC7568180.
- Zhang Y, Lee D, Brimer T, Hussaini M, Sokol L. Genomics of Peripheral T-Cell Lymphoma and Its Implications for Personalized Medicine. Front Oncol. 2020 Jun.10:898. Pubmedid: 32637355. Pmcid: PMC7317006.
- Zhang Y, Song J, Rutenberg D, Sokol L. Hepatic Infiltration with Malignant T-cells Manifesting as Impending Acute Liver Failure in Sezary Syndrome. Mediterr J Hematol Infect Dis. 2020 Jan.12(1):e2020007. Pubmedid: 31934317. Pmcid: PMC6951350.
- Visweshwar N, Zhang Y, Joseph H, Jaglal M, Ayala I. Chronic pain in patients with hemophilia: is it preventable?. Blood Coagul Fibrinolysis. 2020 Aug.31(6):346-352. Pubmedid: 32804455.
- Zhang Y, Swoboda DM, Grover A, Nodzon L, Zhang L, Pinilla-Ibarz J. T315I-mutated myeloid sarcoma. Leuk Res Rep. 2019 Aug.12:100184. Pubmedid: 31485411. Pmcid: PMC6715886.
-
Grants
Title: Enhancing Patient Diversity in the PLIGHT Trial: A Multilevel Strategy for Inclusive Enrollment for Asian Population in the Concurrent Phototherapy and POTELIGEO (mogamulizumab-kpkc) Pilot Study for Early-Stage Mycosis Fungoides
Sponsor: Bristol Myers Squibb Foundation
PI: Zhang, Y.
Title: Evaluating Molecular Biology of Clonal Large Granular Lymphocytic (LGL) Proliferations in Peripheral Blood in Patients with Mycosis Fungoides/Sezary Syndrome (MF/SS)
Sponsor: Amer Society of Clinical Oncology (ASCO)
PI: Zhang, Y.
-
Patient Comments
23 patients rated this provider
The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Learn more about our patient satisfaction surveyComments
Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.
We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.
Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.
Learn more about our patient comments
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:
Learn more about our patient satisfaction survey, ratings and comments